Medical articles today

/* 728x15, */

Boston Scientific Data Show Real-World Survival Rates For Implantable Cardiac Device Patients Exceed Rates From Clinical Trials

/* 468x60, */

Boston Scientific Partnership (NYSE: BSX) announced information from its ALTITUDE Clinical Science program that show real-word survival rates for implantable cardiac device patients exceeding rates from clinical trials. ALTITUDE analyses outcomes data from patients monitored by the LATITUDE(R) Patient State system. Five-year survival degree news for patients using implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) were presented at the Heart Rhythm Sovereign state Scientific Sessions in Boston by Leslie Saxon, M.D., F.A.C.C., Chief, Cardiovascular Medicine at the Cardiovascular and Thoracic Institute, University of Southern California, and chairperson of the ALTITUDE doctor panel.
Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system by reason of its introduction in 2006, making it the most rapidly adopted remote cardiac device monitoring action in the industry(1). The LATITUDE step enables physicians to plan remote follow-ups of implantable cardiac slogan patients to monitor specific device hookup and affection health status. The system can besides detect clinical events between scheduled visits and send substantial data directly to physicians. This regular, in-home monitoring offers convenience and stillness of head for patients.
Findings presented nowadays from ALTITUDE, which analysed almost 86,000 patients monitored by the Freedom system, include:
-- Five-year survival rates for ICD patients of up to 92 percent
-- Five-year survival rates for CRT-D patients of up to 78 percent
"In contrast to clinical trials, the ALTITUDE programme analyzes device therapy in real-world knowledge and offers insights into clinical event rates and disease progression for extensive ICD and CRT-D patient populations," said Dr. Saxon. "This observational cohort study represents the largest cardiac device patient cohort to date and clearly shows survival rates exceed those reported in randomized trials."
"Boston Scientific is notorious for excellence in its clinical trials, such as MADIT, MADIT II, Partner and MADIT-CRT," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "We're also great of our convincing investment in physician evaluation over post-market analysis. The ALTITUDE Clinical Science program serves physicians by enhancing their understanding of device therapy, outcomes and disease succession in real-world device patients monitored by LATITUDE."
Cautionary Statement Regarding Forward-Looking Statements
This press proceeds contains forward-looking statements within the content of Abbreviate 21E of the Securities Alter Naked truth of 1934. Forward-looking statements may be identified by contents adoration "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using dirt available to us at the extent and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. Whether our underlying assumptions turn gone to be incorrect, or provided definite risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, retain affected and in the coming (together with other factors) could alter our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: likely economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial conditions; and, eventual business decisions imaginary by us and our competitors. All of these factors are arduous or impossible to predict accurately and legion of them are beyond our control. For a besides list and description of these and other valuable risks and uncertainties that may overcome our outlook operations, contemplate Object I, Protest 1A- Risk Factors in our most modern Annual Announcement on Configuration 10-K filed with the Securities and Moderate Commission, which we may update in Component II, Item 1A - Risk Factors in Quarterly Reports on Figure 10-Q we have filed or will file thereafter. We disclaim any intention or debt to publicly modernize or revise any forward-looking statements to reflect any alter in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may perturb the likelihood that actual results testament differ from those contained in the forward-looking statements. This cautionary statement is relevant to all forward-looking statements contained in this document.
(1) Data based on number of patients at three oldness post-launch. Counsel on file.
Source: Boston Scientific Corporation
/* 468x60, */


patients, device patients, patients exceed, patients monitored, patients percent, patients oldness, patients latitude, patients monitor, patients implantable, patients exceeding
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy